Tissue Plasminogen Activator Market

Tissue Plasminogen Activator Market, By Drug Type (Alteplase, Reteplase, Tenecteplase), By Application (Ischemic Stroke, Myocardial Infarction, Pulmonary Embolism, Thrombolysis, Others), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)

Tissue plasminogen activator, also known as tissue-type plasminogen activator (tPA), is a serine protease that is present in endothelial cells, the cells that line blood arteries, and is involved in the process of breaking down blood clots (fibrinolysis). Plasminogen is transformed into plasmin by the tPA enzyme. tPA can be employed in studies on embolic or thrombotic stroke.

tPA may be produced by using recombinant biotechnology methods. This kind of tPA is known as recombinant tissue plasminogen activator (rtPA). t-PA is a proteolytic enzyme present in blood and tissues. The primary physiological function of t-PA is the production of plasmin that can break blood clots in the vasculature.

Market Dynamics

Increasing prevalence of ischemic stroke is expected to drive the market growth over frecast period as tissue-type plasminogen activator (tPA) is used to treat ischemic stroke. For instance, in 2022, according to World Stroke Organization (WSO), there are over 7.6 million new ischemic strokes each year worlwide. Ischemic strokes accounted for more than 62% of incident strokes worldwide in 2019. People aged 15 to 49 account for nearly 11% of all ischemic strokes each year.

Moreover, according to the 2022 report from the American Heart Association, there were approximately 244.1 million individuals globally living with ischemic heart disease (IHD) in the year 2020. This condition was found to be more prevalent among males, with approximately 141.0 million affected, compared to females, where the estimated number of affected individuals was 103.1 million.

Key features of the study:

• This report provides an in-depth analysis of the global tissue plasminogen activator market and provides market size (US$ Bn) and compound annual growth rate (CAGR) for the forecast period (2023–2030), considering 2022 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global tissue plasminogen activator market based on the following parameters– company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include Hoffmann-La Roche AG, Boehringer Ingelheim GmbH, CHIESI Farmaceutici S.p.A., Gennova Biopharmaceuticals Ltd, Abbott Laboratories, and Reliance Life Sciences
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• Global tissue plasminogen activator market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global tissue plasminogen activator market

Detailed Segmentation:

• By Drug Type:
• Alteplase
• Reteplase
• Tenecteplase
• By Application:
• Ischemic Stroke
• Myocardial Infarction
• Pulmonary Embolism
• Thrombolysis
• Others
• By Region:
• North America
• Europe
• Asia Pacific
• Latin America
• Middle East
• Africa
• Company Profiles
• F. Hoffmann-La Roche AG.
• Boehringer Ingelheim GmbH
• CHIESI Farmaceutici S.p.A.
• Gennova Biopharmaceuticals Ltd
• Abbott Laboratories
• Reliance Life Sciences